The present invention relates generally to the field of lithium-ion batteries. Specifically, the present invention relates to lithium-ion batteries may be charged at an overpotential to increase the speed of charging.
Lithium-ion batteries include a positive current collector (e.g., aluminum such as an aluminum foil) having an active material provided thereon (e.g., LiCoO2) and a negative current collector (e.g., copper such as a copper foil) having an active material (e.g., a carbonaceous material such as graphite) provided thereon. Together the positive current collector and the active material provided thereon are referred to as a positive electrode, while the negative current collector and the active material provided thereon are referred to as a negative electrode.
During charging and discharging of the battery 10, lithium ions move between the positive electrode 20 and the negative electrode 30. For example, when the battery 10 is discharged, lithium ions flow from the negative electrode 30 to the positive electrode 20. In contrast, when the battery 10 is charged, lithium ions flow from the positive electrode 20 to the negative electrode 30.
As shown in
One difficulty with conventional lithium-ion batteries is that when such a battery is discharged to a point near zero volts, it may exhibit a loss of deliverable capacity and corrosion of the negative electrode current collector (copper) and possibly of the battery case, depending on the material used and the polarity of the case. As shown in
During charging of a conventional lithium-ion battery, it may be necessary to take certain precautions to avoid plating of lithium on the negative electrode. For example, as shown in
The medical device industry produces a wide variety of electronic and mechanical devices for treating patient medical conditions. Depending upon the medical condition, medical devices can be surgically implanted or connected externally to the patient receiving treatment. Clinicians use medical devices alone or in combination with drug therapies and surgery to treat patient medical conditions. For some medical conditions, medical devices provide the best, and sometimes the only, therapy to restore an individual to a more healthful condition and a fuller life.
It may be desirable to provide a source of battery power for such medical devices, including implantable medical devices. In such cases, it may be advantageous to provide a battery that may be recharged relatively quickly such that inconvenience to the patient may be reduced. It would also be advantageous to provide a battery that may be charged at a greater rate than conventional lithium-ion batteries without significant risk of plating lithium on the negative electrode of the battery. It would also be advantageous to provide a medical device (e.g., an implantable medical device) that utilizes such a battery.
An exemplary embodiment of the present invention relates to a method for charging an implantable medical device. The method includes charging a lithium-ion battery provided in a medical device, the lithium-ion battery having a negative electrode with a lithium titanate active material. For at least a portion of the charging, the potential of the negative electrode is more than approximately 70 millivolts below the equilibrium potential of the negative electrode.
Another exemplary embodiment of the present invention relates to a method of charging a lithium-ion battery that includes charging a lithium-ion battery in a charging operation, the lithium-ion battery including a negative electrode that comprises a lithium titanate material. For at least a portion of the charging operation the overpotential of the negative electrode is greater than approximately 70 millivolts. The lithium battery is included in an implantable medical device and the charging operation does not result in lithium plating at the negative electrode.
Another exemplary embodiment of the present invention relates to a method of charging a lithium-ion battery that includes inductively charging a lithium-ion battery according to a charging routine that provides an overpotential of at least 70 millivolts to a negative electrode of the battery for at least a portion of the charging routine, the lithium-ion battery comprising a lithium titanate negative active material.
With reference to
The battery 200 includes at least one positive electrode 210 and at least one negative electrode 220. The electrodes may be provided as flat or planar components of the battery 200, may be wound in a spiral or other configuration, or may be provided in a folded configuration. For example, the electrodes may be wrapped around a relatively rectangular mandrel such that they form an oval wound coil for insertion into a relatively prismatic battery case. According to other exemplary embodiments, the battery may be provided as a button cell battery, a thin film solid state battery, or as another lithium-ion battery configuration.
The battery case (not shown) may be made of a metal such as aluminum or an aluminum alloy or another metal. According to an exemplary embodiment, the battery case may be made of titanium, a titanium alloy, or stainless steel. According to another exemplary embodiment, the battery case may be made of a plastic material or a plastic-foil laminate material (e.g., an aluminum foil provided intermediate a polyolefin layer and a polyester layer).
According to an exemplary embodiment, the negative electrode is coupled to an aluminum case by a member or tab comprising aluminum or an aluminum alloy. An aluminum or aluminum alloy member or tab may be coupled or attached to the positive electrode. The tabs may serve as terminals for the battery according to an exemplary embodiment.
The dimensions of the battery 200 may differ according to a variety of exemplary embodiments. For example, according to one exemplary embodiment in which the electrodes are wound such that they may be provided in a relatively prismatic battery case, the battery has dimensions of between approximately 30-40 mm by between approximately 20-30 mm by between approximately 5-7 mm. According to another exemplary embodiment, the dimensions of the battery are approximately 20 mm by 20 mm by 3 mm. According to another exemplary embodiment, a battery may be provided in the form of a button cell type battery having a diameter of approximately 30 mm and a thickness of approximately 3 mm. It will be appreciated by those of skill in the art that such dimensions and configurations as are described herein are illustrative only, and that batteries in a wide variety of sizes, shapes, and configurations may be produced in accordance with the novel concepts described herein.
An electrolyte 230 is provided intermediate or between the positive and negative electrodes to provide a medium through which lithium ions may travel. The electrolyte may be a liquid (e.g., a lithium salt dissolved in one or more non-aqueous solvents). According to an exemplary embodiment, the electrolyte may be a mixture of propylene carbonate (PC), ethylene carbonate (EC), diethyl carbonate (DEC) and a 1.0 M salt of LiPF6. According to another exemplary embodiment, an electrolyte may be used that does not use constituents that may commonly be used in lithium batteries (e.g., ethylene carbonate, vinylene carbonate, lithium bis-oxalatoborate salt (sometimes referred to as LiBOB), etc.).
Various other electrolytes may be used according to other exemplary embodiments. According to an exemplary embodiment, the electrolyte may be a lithium salt dissolved in a polymeric material such as poly(ethylene oxide) or silicone. According to another exemplary embodiment, the electrolyte may be an ionic liquid such as N-methyl-N-alkylpyrrolidinium bis(trifluoromethanesulfonyl)imide salts. According to another exemplary embodiment, the electrolyte may be a solid state electrolyte such as a lithium-ion conducting glass such as lithium phosphorous oxynitride (LiPON). According to another exemplary embodiment, the electrolyte may be a 1:1 mixture of ethylene carbonate to diethylene carbonate (EC:DEC) in a 1.0 M salt of LiPF6. According to another exemplary embodiment, the electrolyte may include a polypropylene carbonate solvent and a lithium bis-oxalatoborate salt. According to other exemplary embodiments, the electrolyte may comprise one or more of a PVDF copolymer, a PVDF-polyimide material, and organosilicon polymer, a thermal polymerization gel, a radiation cured acrylate, a particulate with polymer gel, an inorganic gel polymer electrolyte, an inorganic gel-polymer electrolyte, a PVDF gel, polyethylene oxide (PEO), a glass ceramic electrolyte, phosphate glasses, lithium conducting glasses, lithium conducting ceramics, and an inorganic ionic liquid gel, among others.
A separator 250 is provided intermediate or between the positive electrode 210 and the negative electrode 220. According to an exemplary embodiment, the separator 250 is a polymeric material such as a polypropylene/polyethelene copolymer or another polyolefin multilayer laminate that includes micropores formed therein to allow electrolyte and lithium ions to flow from one side of the separator to the other. The thickness of the separator 250 is between approximately 10 micrometers (μm) and 50 μm according to an exemplary embodiment. According to a particular exemplary embodiment, the thickness of the separator is approximately 25 μm and the average pore size of the separator is between approximately 0.02 μm and 0.1 μm.
The positive electrode 210 includes a current collector 212 made of a conductive material such as a metal. According to an exemplary embodiment, the current collector 212 comprises aluminum or an aluminum alloy.
According to an exemplary embodiment, the thickness of the current collector 212 is between approximately 5 μm and 75 μm. According to a particular exemplary embodiment, the thickness of the current collector 212 is approximately 20 μm. It should also be noted that while the positive current collector 212 has been illustrated and described as being a thin foil material, the positive current collector may have any of a variety of other configurations according to various exemplary embodiments. For example, the positive current collector may be a grid such as a mesh grid, an expanded metal grid, a photochemically etched grid, or the like.
The current collector 212 has a layer of active material 216 provided thereon (e.g., coated on the current collector). While
According to an exemplary embodiment, the active material 216 is a material or compound that includes lithium. The lithium included in the primary active material 216 may be doped and undoped during discharging and charging of the battery, respectively. According to an exemplary embodiment, the primary active material 216 is lithium cobalt oxide (LiCoO2). According to another exemplary embodiment, the active material provided on the current collector 212 is LiMn2O4. According to another exemplary embodiment, the active material provided on the current collector 212 is a material of the form LiCoxNi(1−x)O2, where x is between approximately 0.05 and 0.8. According to another exemplary embodiment, the active material provided on the positive current collector 212 is a material of the form LiNixCoyMN(1−x−y)O2 (e.g., LiNi1/3Co1/3Mn1/3O2). According to another exemplary embodiment, the active material provided on the current collector 212 is a metal-doped variety of one of these materials, such as a material of the form LiMxCoyNi(1−x−y)O2, where M is aluminum or titanium and x is between approximately 0.05 and 0.3 and y is between approximately 0.1 and 0.3.
For certain applications, it may be desirable to provide a battery having a cell voltage of greater than approximately 3 volts. In such cases, a higher-voltage active material may be utilized on the positive current collector, such as a material in the form Li2−xCoyFezMn4−(y+z)O8 (e.g., Li2Co0.4Fe0.4Mn3.2O8). It is believed that such an active material may charge up to 5.2 volts versus a lithium reference electrode, making it possible to obtain an overall cell voltage of up to approximately 3.7 volts. Other relatively high-voltage active materials that may be used for the positive electrode include LiCoPO4; LiNiPO4; Li2CoPO4F; Li[Ni0.2Li0.2Mn0.6]O2; and LiCoxMn2−xO4 (e.g., LiCo0.3Mn1.7O4).
According to various other exemplary embodiments, the active material may include a material such as a material of the form Li1−xMO2 where M is a metal (e.g., LiCoO2, LiNiO2, and LiMnO2), a material of the form Li1−w(M′xM″y)O2 where M′ and M″ are different metals (e.g., Li(CrxMn1−x)O2, Li(AlxMn1−x)O2, Li(CoxM1−x) O2 where M is a metal, Li(CoxNi1−x)O2, and Li(CoxFe1−x)O2)), a material of the form Li1−w(MnxNiyCoz)O2 (e.g., Li(Mn1/3Ni1/3Co1/3)O2, Li(Mn1/3Ni1/3Co1/3−xMgx)O2, Li(Mn0.4Ni0.4Co0.2)O2, and Li(Mn0.1Ni0.1Co0.8)O2), a material of the form Li1−w(MnxNixCo1−2x)O2, a material of the form Li1−w(MnxNiyCozAlw)O2, a material of the form Li1−w(NixCoyAlz)O2 (e.g., Li(Ni0.8Co0.15Al0.05)O2), a material of the form Li1−w(NixCoyMz)O2 where M is a metal, a material of the form Li1−w(NixMnyMz)O2 where M is a metal, a material of the form Li(Nix-yMnyCr2−x)O4, LiMn2O4, a material of the form LiM′M″2O4 where M′ and M″ are different metals (e.g., LiMn2−y−zNiyO4, LizO4, LiNiCuO4, LiMn1−x AlxO4, LiNi0.5Ti0.5O4, and Li1.05Al0.1Mn1.85O4−zFz), Li2MnO3, a material of the form LixVyOz (e.g., LiV3O8, LiV2O5, and LiV6O13), a material of the form LiMPO4 where M is a metal or LiMx′M″1−xPO4 where M′ and M″ are different metals (e.g., LiFePO4, LiFexM1−xPO4 where M is a metal, LiVOPO4, and Li3V2(PO4)3, and LiMPO4x, where M is a metal such as iron or vanadium and X is a halogen such as fluorine, and combinations thereof.
A binder material may also be utilized in conjunction with the layer of active material 216 to bond or hold the various electrode components together. For example, according to an exemplary embodiment, the layer of active material may include a conductive additive such as carbon black and a binder such as polyvinylidine fluoride (PVDF) or an elastomeric polymer.
According to an exemplary embodiment, the thickness of the layer of active material 216 is between approximately 0.1 μm and 3 mm. According to another exemplary embodiment, the thickness of the layer of active material 216 is between approximately 25 μm and 300 μm. According to a particular exemplary embodiment, the thickness of the layer of active material 216 is approximately 75 μm.
The negative electrode 220 includes a current collector 222 that is made of a conductive material such as a metal. According to an exemplary embodiment, the current collector 222 is aluminum or an aluminum alloy. One advantageous feature of utilizing an aluminum or aluminum alloy current collector is that such a material is relatively inexpensive and may be relatively easily formed into a current collector. Other advantageous features of using aluminum or an aluminum alloy includes the fact that such materials may have a relatively low density, are relatively highly conductive, are readily weldable, and are generally commercially available. According to another exemplary embodiment, the current collector 222 is titanium or a titanium alloy. According to another exemplary embodiment, the current collector 222 is silver or a silver alloy.
While the negative current collector 222 has been illustrated and described as being a thin foil material, the negative current collector may have any of a variety of other configurations according to various exemplary embodiments. For example, the positive current collector may be a grid such as a mesh grid, an expanded metal grid, a photochemically etched grid, or the like.
According to an exemplary embodiment, the thickness of the current collector 222 is between approximately 100 nm and 100 μm. According to another exemplary embodiment, the thickness of the current collector 222 is between approximately 5 μm and 25 μm. According to a particular exemplary embodiment, the thickness of the current collector 222 is approximately 10 μm.
The negative current collector 222 has an active material 224 provided thereon. While
According to an exemplary embodiment, the negative active material 224 is a lithium titanate material such as Li4Ti5O12 (sometimes referred to as Li1+x[Li1/3Ti5/3]O4, with 0≦x<1). Other lithium titanate materials which may be suitable for use as the negative active material may include one or more of the following lithium titanate spinel materials: HxLiy−xTiOxO4, HxLiy−xTiOxO4, Li4MxTi5−xO12, LixTiyO4, LixTiyO4, Li4[Ti1.67Li0.33−yMy]O4, Li2TiO3, Li4Ti4.75V0.25O12, Li4Ti4.75Fe0.25O11.88, Li4Ti4.5Mn0.5O12, and LiM′M″XO4 (where M′ is a metal such as nickel, cobalt, iron, manganese, vanadium, copper, chromium, molybdenum, niobium, or combinations thereof, M″ is an optional three valent non-transition metal, and X is zirconium, titanium, or a combination of these two). Note that such lithium titanate spinel materials may be used in any state of lithiation (e.g., Li4+xTi5O12, where 0≧x≧3).
According to an exemplary embodiment, the lithium titanate may be provided such that at least five percent is in the form of lithium titanate nanoparticles (e.g., having a particle size of less than approximately 500 nanometers). The use of such nonoparticles is intended to provide greater surface area for doping and undoping of lithium ions.
A binder material may also be utilized in conjunction with the layer of active material 224. For example, according to an exemplary embodiment, the layer of active material may include a binder such as polyvinylidine fluoride (PVDF) or an elastomeric polymer. The active material 224 may also include a conductive material such as carbon (e.g., carbon black) at weight loadings of between zero and ten percent to provide increased electronic conductivity.
According to various exemplary embodiments, the thickness of the active material 224 is between approximately 0.1 μm and 3 mm. According to other exemplary embodiments, the thickness of the active material 224 may be between approximately 25 μm and 300 μm. According to another exemplary embodiment, the thickness of the active material 224 may be between approximately 20 μm and 90 μm, and according to a particular exemplary embodiment, approximately 75 μm.
Curve 320 represents the electrode potential for a negative electrode that includes an aluminum current collector having a lithium titanate active material provided thereon. The difference between curves 310 and 320 is representative of the overall cell voltage of the battery, and is represented as curve 340 in
As shown in
One potential advantageous feature of utilizing a lithium titanate material for the negative electrode active material is that more favorable design rules may be possible. For example, in conventional lithium-ion cells, the negative electrode must overlap the positive electrode by approximately 1 mm on all edges in order to avoid plating of lithium. For applications in which space is a concern, this may result in significant wasted volume (e.g., for a cranial implant cell that is approximately 22 mm high, this may result in wasted volume of approximately 10 percent). Because use of a titanate material reduces the risk of lithium plating, it is believed that the design requirement of overlapping positive and negative electrodes may be unnecessary, thus allowing the production of lithium-ion batteries with improved energy density.
The lithium diffusion coefficient for lithium titanate materials may be on the order of approximately 2×10−8 cm2/s, which is approximately ten times that of carbon, thus allowing a comparatively rapid sustained rate capability. The use of such materials may allow the manufacture of batteries having lower surface area electrodes while still achieving adequate power and recharge rates. According to an exemplary embodiment, a battery utilizes monolithic (i.e., single-plate) electrodes in a coin cell or a foil laminate package. Due to the comparatively rapid sustained rate capability of the lithium titanate material, the battery may be relatively thin (e.g., approximately 1 mm) and inexpensive. Further, according to other exemplary embodiments, batteries may be produced in contoured shapes, which may allow for packaging of such batteries unobtrusively and in unconventional ways in a device (such as along an inner surface of a device housing or case such as a housing for a medical device such as a pacemaker). This may be especially advantageous in a device such as a cranial implant, where it may be desirable to provide the device having a contour to match the curvature of the skull.
Conventional lithium-ibn cells are balanced with a nominal excess negative active material of between approximately five and ten percent to avoid plating of lithium. The use of excess active material results in a larger battery, which results in a cell having reduced energy density. According to an exemplary embodiment, a battery or cell using a lithium titanate active material on an aluminum negative current collector may be produced without excess negative active material (e.g., as a “balanced design”).
Another advantageous feature of using a lithium titanate material is that it is believed that when used in a negative electrode of a lithium-ion battery, such materials will cycle lithium at a potential plateau of about 1.55 volts (see, e.g.,
Because such lithium-ion batteries cycle lithium at a plateau of about 1.55 volts, they are believed to be less susceptible to lithium plating. Lithium plating is a well-known phenomenon that can lead to loss in performance of lithium ion batteries. Lithium-ion batteries using lithium titanate as negative active material are believed to be less likely to result in plating of lithium (which occurs at 0 volts versus a lithium reference) while being charged. For example, lithium batteries using lithium titantate negative active material may be charged such that, at one or more points in a charging operation, the potential of the negative electrode is more than 70 millivolts lower than its equilibrium (i.e., open circuit) potential. Dashed curve 322 shown in
Another advantage of using a lithium titanate material instead of a carbonaceous material for the negative active material is that it is believed that the use of a lithium titanate material allows for charging and discharging of the battery at higher rates than is capable using carbonaceous materials. For example, a common upper limit for the rate of charge in lithium ion batteries is about 1 C (meaning that the battery can be fully charged from the discharged state in one hour). Conversely, it has been reported in literature that lithium titanate may be charged at rates up to 10 C (i.e., attaining full charge in 1/10 hour, or six minutes). One potential reason for this is that negative electrodes utilizing a lithium titanate active material are believed to be less susceptible to the risk of lithium plating. The ability to recharge a battery more quickly may substantially increase the functionality of devices that employ such a battery.
It is also believed that the use of negative electrodes that include a lithium titanate active material may allow for charging of the battery at voltages that exceed those used in the charging of batteries in which the negative electrodes utilize carbon active materials. One potential advantage of such a property is that nonhermetic cells (e.g., cells using a rivet polymer feedthrough, foil package, etc.) may be produced. Nonhermetic cells typically have greater energy density than other cells, are relatively inexpensive to manufacture, and may be produced using a wider variety of materials (e.g, polymer foil laminates, etc.). In medical applications in particular, such cells have conventionally utilized with polymer or gel electrolytes which have lower vapor pressure to provide a reduced risk of leakage. However, such electrolytes are typically less conductive than liquid electrolytes, resulting in relatively low power and/or charge rate. By utilizing a battery that includes a lithium titanate active material on an aluminum current collector, the charge voltage of the cell may be increased to compensate for resistive losses (e.g., an IR drop) in the electrolyte.
Because of the various potentially advantageous features described above for batteries utilizing a lithium titanate negative active material (e.g., provided on an aluminum negative current collector and used with a positive electrode having an active material such as LiCoO2 provided thereon), it is believed that a number of charging routines may be used that may not otherwise be utilized with conventional lithium-ion batteries (e.g., batteries that do not use a lithium titantate negative active material). Non-exclusive exemplary embodiments of such charging routines are illustrated in
To determine the point at which charging of the battery as shown in
To determine the point at which charging of the battery as shown in
To determine the point at which charging of the battery as shown in
To determine the point at which charging of the battery as shown in
It should be noted that similar techniques to those shown and described with respect to
While
It should be noted that the routines or algorithms shown and described with respect to
Single plate lithium ion cells with a reference electrode were fabricated in stainless steel cans. The positive electrode comprised a coating of LiCoO2, powdered graphite and PVDF on an aluminum current collector. The negative electrode consisted of a coating of Li4Ti5O12, carbon black, and PVDF on an aluminum foil current collector. The Li4Ti5O12 was obtained under the trade name “EXM 1037”, commercially available from Sud-Chemie of Munich, Germany). The Li4Ti5O12 included about 40 volume percent of particles less than 500 nm, as measured by laser diffraction. The mass deposition of the positive coating was about 22 mg/cm2, and the calendered thickness of the coating was about 70 microns. The mass deposition of the negative electrode was about 17 mg/cm2 and the calendared thickness was about 75 microns. The electrode active area was about 5 cm2.
The reference electrode consisted of a nugget of metallic lithium on the end of a feedthrough pin, placed in the headspace of the cell. Cells were activated using an electrolyte consisting of a 1 M LiPF6 in a mixture of propylene carbonate, ethylene carbonate and diethyl carbonate. The cell was formed and cycled using an ARBIN BT-2000 battery cycler at 37° C. During cycling, the current, the cell voltage and potential of the negative electrode versus the Li reference electrode were monitored. After completion of twelve conditioning cycles, the battery underwent two cycles to compare the charge rate under a constant current (0.5 mA) and constant voltage (3 V) charging condition.
According to an exemplary embodiment, lithium-ion batteries and charging rountines such as those described above may be used in conjunction with medical devices such as medical devices that may be implanted in the human body (referred to as “implantable medical devices” or “IMDs”). One advantage of using lithium-ion batteries and charging routines such as those described herein with IMDs is that the relatively quick charge times may act to reduce the potential inconvenience to the patient.
The device 410 includes a container or housing 414 that is hermetically sealed and biologically inert according to an exemplary embodiment. The container may be made of a conductive material. One or more leads 416 electrically connect the device 410 and to the patient's heart 420 via a vein 422. Electrodes 417 are provided to sense cardiac activity and/or provide an electrical potential to the heart 420. At least a portion of the leads 416 (e.g., an end portion of the leads shown as exposed electrodes 417) may be provided adjacent or in contact with one or more of a ventricle and an atrium of the heart 420.
The device 410 includes a battery 440 provided therein to provide power for the device 410. According to another exemplary embodiment, the battery 440 may be provided external to the device or external to the patient 430 (e.g., to allow for removal and replacement and/or charging of the battery). The size and capacity of the battery 440 may be chosen based on a number of factors, including the amount of charge required for a given patient's physical or medical characteristics, the size or configuration of the device, and any of a variety of other factors. According to an exemplary embodiment, the battery is a 5 mAh battery. According to another exemplary embodiment, the battery is a 300 mAh battery. According to various other exemplary embodiments, the battery may have a capacity of between approximately 1 and 1000 mAh.
According to other exemplary embodiments, more than one battery may be provided to power the device 410. In such exemplary embodiments, the batteries may have the same capacity or one or more of the batteries may have a higher or lower capacity than the other battery or batteries. For example, according to an exemplary embodiment, one of the batteries may have a capacity of approximately 500 mAh while another of the batteries may have a capacity of approximately 75 mAh.
According to another exemplary embodiment shown in
An INS generates one or more electrical stimulation signals that are used to influence the human nervous system or organs. Electrical contacts carried on the distal end of a lead are placed at the desired stimulation site such as the spine or brain and the proximal end of the lead is connected to the INS. The INS is then surgically implanted into an individual such as into a subcutaneous pocket in the abdomen, pectoral region, or upper buttocks area. A clinician programs the INS with a therapy using a programmer. The therapy configures parameters of the stimulation signal for the specific patient's therapy. An INS can be used to treat conditions such as pain, incontinence, movement disorders such as epilepsy and Parkinson's disease, and sleep apnea. Additional therapies appear promising to treat a variety of physiological, psychological, and emotional conditions. Before an INS is implanted to deliver a therapy, an external screener that replicates some or all of the INS functions is typically connected to the patient to evaluate the efficacy of the proposed therapy.
The INS 500 includes a lead extension 522 and a stimulation lead 524. The stimulation lead 524 is one or more insulated electrical conductors with a connector 532 on the proximal end and electrical contacts (not shown) on the distal end. Some stimulation leads are designed to be inserted into a patient percutaneously, such as the Model 3487A Pisces-Quad® lead available from Medtronic, Inc. of Minneapolis Minn., and stimulation some leads are designed to be surgically implanted, such as the Model 3998 Specify® lead also available from Medtronic.
Although the lead connector 532 can be connected directly to the INS 500 (e.g., at a point 536), typically the lead connector 532 is connected to a lead extension 522. The lead extension 522, such as a Model 7495 available from Medtronic, is then connected to the INS 500.
Implantation of an INS 520 typically begins with implantation of at least one stimulation lead 524, usually while the patient is under a local anesthetic. The stimulation lead 524 can either be percutaneously or surgically implanted. Once the stimulation lead 524 has been implanted and positioned, the stimulation lead's 524 distal end is typically anchored into position to minimize movement of the stimulation lead 524 after implantation. The stimulation lead's 524 proximal end can be configured to connect to a lead extension 522.
The INS 500 is programmed with a therapy and the therapy is often modified to optimize the therapy for the patient (i.e., the INS may be programmed with a plurality of programs or therapies such that an appropriate therapy may be administered in a given situation). In the event that the battery 502 requires recharging, an external lead (not shown) may be used to electrically couple the battery to a charging device or apparatus.
A physician programmer and a patient programmer (not shown) may also be provided to allow a physician or a patient to control the administration of various therapies. A physician programmer, also known as a console programmer, uses telemetry to communicate with the implanted INS 500, so a clinician can program and manage a patient's therapy stored in the INS 500, troubleshoot the patient's INS 500 system, and/or collect data. An example of a physician programmer is a Model 7432 Console Programmer available from Medtronic. A patient programmer also uses telemetry to communicate with the INS 500, so the patient can manage some aspects of her therapy as defined by the clinician. An example of a patient programmer is a Model 7434 Itrel® 3 EZ Patient Programmer available from Medtronic.
While the medical devices described herein (e.g., systems 400 and 500) are shown and described as a defibrillator and a neurological stimulation device, it should be appreciated that other types of implantable medical devices may be utilized according to other exemplary embodiments, such as pacemakers, cardioverters, cardiac contractility modules, drug administering devices, diagnostic recorders, cochlear implants, and the like for alleviating the adverse effects of various health ailments. According to still other embodiments, non-implantable medical devices or other types of devices may utilize batteries as are shown and described in this disclosure.
It is also contemplated that the medical devices described herein may be charged or recharged when the medical device is implanted within a patient. That is, according to an exemplary embodiment, there is no need to disconnect or remove the medical device from the patient in order to charge or recharge the medical device. For example, transcutaneous energy transfer (TET) may be used, in which magnetic induction is used to deliver energy from outside the body to the implanted battery, without the need to make direct physical contact to the implanted battery, and without the need for any portion of the implant to protrude from the patient's skin. According to another exemplary embodiment, a connector may be provided external to the patient's body that may be electrically coupled to a charging device in order to charge or recharge the battery. According to other exemplary embodiments, medical devices may be provided that may require removal or detachment from the patient in order to charge or recharge the battery.
Another application in which the use of batteries such as those described herein may be in multiple-battery systems in which two or more batteries are used (e.g., as a power module for the multiple-battery device). An example of this would be an implantable cardioverter defibrillator (ICD) which contains two batteries. ICD's operate over most of their lifetime in a low-power mode but must supply relatively high power (e.g., 10 watts) for periods of a few seconds each when a defibrillation shock is needed. A low or medium rate primary cell (for example a lithium battery with a cathode consisting of CFx, CFx-SVO hybrid, or lithium/MnO2) acts as the energy module, supplying the majority of the energy to the device. However, the energy module is incapable of sustaining high power. It is therefore connected in parallel to the lithium ion cell such as that disclosed herein (e.g., a battery having a lithium titanate active material provided on an aluminum, silver, or titanium negative current collector and a positive electrode having an active material such as those described herein provided thereon), which acts as the power module during high drain applications. The combined two-cell battery has both high energy and power density. When connecting two cells in parallel, it is essential that the two cell voltages are compatible with each other. With a standard lithium ion cell, the voltage is too high (about 3.7 V) to be connected in parallel with most lithium primary cells. Doing so would result in damage to the primary cells and possibly harm to the patient. However, utilizing a lithium ion cell such as that disclosed herein may allow for a relatively safe connection to a lithium primary cell as the voltage ranges of the two cell types overlap perfectly.
It is important to note that the construction and arrangement of the lithium-ion battery as shown and described with respect to the various exemplary embodiments is illustrative only. Although only a few embodiments of the present inventions have been described in detail in this disclosure, those skilled in the art who review this disclosure will readily appreciate that many modifications are possible (e.g., variations in sizes, dimensions, structures, shapes and proportions of the various elements, values of parameters, mounting arrangements, use of materials, colors, orientations, etc.) without materially departing from the novel teachings and advantages of the subject matter recited in the claims. Accordingly, all such modifications are intended to be included within the scope of the present invention as defined in the appended claims. Other substitutions, modifications, changes and omissions may be made in the design, operating conditions and arrangement of the preferred and other exemplary embodiments without departing from the scope of the present invention.
This Application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 60/624,075 filed Oct. 29, 2004 and U.S. Provisional Patent Application No. 60/647,292 filed Jan. 26, 2005, each of which is incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3791867 | Broadhead et al. | Feb 1974 | A |
| 3864167 | Broadhead et al. | Feb 1975 | A |
| 3898096 | Herédy et al. | Aug 1975 | A |
| 4009052 | Whittingham | Feb 1977 | A |
| 4048397 | Rothbauer | Sep 1977 | A |
| 4049887 | Whittingham | Sep 1977 | A |
| 4113921 | Goldstein et al. | Sep 1978 | A |
| 4194062 | Carides et al. | Mar 1980 | A |
| 4202702 | Nuss | May 1980 | A |
| 4340652 | Raistrick et al. | Jul 1982 | A |
| 4446212 | Kaun | May 1984 | A |
| 4464447 | Lazzari et al. | Aug 1984 | A |
| 4507371 | Thackeray et al. | Mar 1985 | A |
| 4547442 | Besenhard et al. | Oct 1985 | A |
| 4555456 | Kanehori et al. | Nov 1985 | A |
| 4668595 | Yoshino et al. | May 1987 | A |
| 4764437 | Kaun | Aug 1988 | A |
| 4830939 | Lee et al. | May 1989 | A |
| H723 | Plichta et al. | Jan 1990 | H |
| 5053297 | Yamahira et al. | Oct 1991 | A |
| 5077151 | Yasuda et al. | Dec 1991 | A |
| 5147737 | Post et al. | Sep 1992 | A |
| 5147739 | Beard | Sep 1992 | A |
| 5160712 | Thackeray et al. | Nov 1992 | A |
| 5162170 | Miyabayashi et al. | Nov 1992 | A |
| 5169736 | Bittihn et al. | Dec 1992 | A |
| 5176969 | Miyabayashi et al. | Jan 1993 | A |
| 5187033 | Koshiba | Feb 1993 | A |
| 5187035 | Miyabayashi et al. | Feb 1993 | A |
| 5196279 | Tarascon | Mar 1993 | A |
| 5264201 | Dahn et al. | Nov 1993 | A |
| 5284721 | Beard | Feb 1994 | A |
| 5296318 | Gozdz et al. | Mar 1994 | A |
| 5300373 | Shackle | Apr 1994 | A |
| 5322746 | Wainwright | Jun 1994 | A |
| 5340666 | Tomantschger et al. | Aug 1994 | A |
| 5401598 | Miyabayashi et al. | Mar 1995 | A |
| 5411537 | Munshi et al. | May 1995 | A |
| 5418090 | Koksbang et al. | May 1995 | A |
| 5498489 | Dasgupta et al. | Mar 1996 | A |
| 5510212 | Delnick et al. | Apr 1996 | A |
| 5525441 | Reddy et al. | Jun 1996 | A |
| 5545468 | Koshiba et al. | Aug 1996 | A |
| 5547785 | Yumiba et al. | Aug 1996 | A |
| 5569553 | Smesko et al. | Oct 1996 | A |
| 5576608 | Nagai et al. | Nov 1996 | A |
| 5652072 | Lamanna et al. | Jul 1997 | A |
| 5670862 | Lewyn | Sep 1997 | A |
| 5691081 | Krause et al. | Nov 1997 | A |
| 5744264 | Barker | Apr 1998 | A |
| 5776628 | Kraft et al. | Jul 1998 | A |
| 5882218 | Reimers | Mar 1999 | A |
| 5888665 | Bugga et al. | Mar 1999 | A |
| 5911947 | Mitchell | Jun 1999 | A |
| 5935724 | Spillman et al. | Aug 1999 | A |
| 5935728 | Spillman et al. | Aug 1999 | A |
| 5968681 | Miura et al. | Oct 1999 | A |
| 6001507 | Ono et al. | Dec 1999 | A |
| 6007947 | Mayer | Dec 1999 | A |
| 6025093 | Herr | Feb 2000 | A |
| 6060186 | Broussely et al. | May 2000 | A |
| 6120938 | Atsumi et al. | Sep 2000 | A |
| 6139815 | Atsumi et al. | Oct 2000 | A |
| 6165638 | Spillman et al. | Dec 2000 | A |
| 6171729 | Gan et al. | Jan 2001 | B1 |
| 6203947 | Peled et al. | Mar 2001 | B1 |
| 6203994 | Epps et al. | Mar 2001 | B1 |
| 6207327 | Takada et al. | Mar 2001 | B1 |
| 6221531 | Vaughey et al. | Apr 2001 | B1 |
| 6228536 | Wasynczuk | May 2001 | B1 |
| 6258473 | Spillman et al. | Jul 2001 | B1 |
| 6265100 | Saaski et al. | Jul 2001 | B1 |
| 6274271 | Koshiba et al. | Aug 2001 | B1 |
| 6287721 | Xie et al. | Sep 2001 | B1 |
| 6316145 | Kida et al. | Nov 2001 | B1 |
| 6335115 | Meissner | Jan 2002 | B1 |
| 6372384 | Fujimoto et al. | Apr 2002 | B1 |
| 6379842 | Mayer | Apr 2002 | B1 |
| 6451480 | Gustafson et al. | Sep 2002 | B1 |
| 6453198 | Torgerson et al. | Sep 2002 | B1 |
| 6461751 | Boehm et al. | Oct 2002 | B1 |
| 6461757 | Sasayama et al. | Oct 2002 | B1 |
| 6475673 | Yamawaki et al. | Nov 2002 | B1 |
| 6489062 | Watanabe | Dec 2002 | B1 |
| 6528208 | Thackeray et al. | Mar 2003 | B1 |
| 6553263 | Meadows et al. | Apr 2003 | B1 |
| 6596439 | Tsukamoto et al. | Jul 2003 | B1 |
| 6645675 | Munshi | Nov 2003 | B1 |
| 6677083 | Suzuki et al. | Jan 2004 | B2 |
| 6706445 | Barker et al. | Mar 2004 | B2 |
| 6720112 | Barker et al. | Apr 2004 | B2 |
| 6730437 | Leising et al. | May 2004 | B2 |
| 6737191 | Gan et al. | May 2004 | B2 |
| 6759168 | Yamasaki et al. | Jul 2004 | B2 |
| 6761744 | Tsukamoto et al. | Jul 2004 | B1 |
| 6777132 | Barker et al. | Aug 2004 | B2 |
| 6824920 | Iwamoto et al. | Nov 2004 | B1 |
| 6849360 | Marple | Feb 2005 | B2 |
| 6942949 | Besenhard et al. | Sep 2005 | B2 |
| 7029793 | Nakagawa et al. | Apr 2006 | B2 |
| 7101642 | Tsukamoto et al. | Sep 2006 | B2 |
| 7157185 | Marple | Jan 2007 | B2 |
| 7191008 | Schmidt et al. | Mar 2007 | B2 |
| 7211350 | Amatucci | May 2007 | B2 |
| 7337010 | Howard et al. | Feb 2008 | B2 |
| 7459235 | Choi et al. | Dec 2008 | B2 |
| 20010008725 | Howard | Jul 2001 | A1 |
| 20010012590 | Ehrlich | Aug 2001 | A1 |
| 20010021472 | Barker et al. | Sep 2001 | A1 |
| 20010031401 | Yamawaki et al. | Oct 2001 | A1 |
| 20030025482 | Tsukamoto et al. | Feb 2003 | A1 |
| 20030104282 | Xing et al. | Jun 2003 | A1 |
| 20030157410 | Jarvis et al. | Aug 2003 | A1 |
| 20030215716 | Suzuki et al. | Nov 2003 | A1 |
| 20040023117 | Imachi et al. | Feb 2004 | A1 |
| 20040096745 | Shibano et al. | May 2004 | A1 |
| 20040147971 | Greatbatch et al. | Jul 2004 | A1 |
| 20040147972 | Greatbatch et al. | Jul 2004 | A1 |
| 20040158296 | Greatbatch et al. | Aug 2004 | A1 |
| 20040168307 | Hong | Sep 2004 | A1 |
| 20040176818 | Wahlstrand et al. | Sep 2004 | A1 |
| 20040197657 | Spitler et al. | Oct 2004 | A1 |
| 20050031919 | Ovshinsky et al. | Feb 2005 | A1 |
| 20050069777 | Takami et al. | Mar 2005 | A1 |
| 20050130043 | Gao et al. | Jun 2005 | A1 |
| 20050147889 | Ohzuku et al. | Jul 2005 | A1 |
| 20050164082 | Kishi et al. | Jul 2005 | A1 |
| 20050244716 | Ogawa et al. | Nov 2005 | A1 |
| 20060024582 | Li et al. | Feb 2006 | A1 |
| 20060046149 | Yong et al. | Mar 2006 | A1 |
| 20060068282 | Kishi et al. | Mar 2006 | A1 |
| 20060093871 | Howard et al. | May 2006 | A1 |
| 20060093872 | Howard et al. | May 2006 | A1 |
| 20060093873 | Howard et al. | May 2006 | A1 |
| 20060093894 | Scott et al. | May 2006 | A1 |
| 20060093913 | Howard et al. | May 2006 | A1 |
| 20060093916 | Howard et al. | May 2006 | A1 |
| 20060093917 | Howard et al. | May 2006 | A1 |
| 20060093918 | Howard et al. | May 2006 | A1 |
| 20060093921 | Scott et al. | May 2006 | A1 |
| 20060093923 | Howard et al. | May 2006 | A1 |
| 20060095094 | Howard et al. | May 2006 | A1 |
| 20060216612 | Jambunathan et al. | Sep 2006 | A1 |
| 20060234125 | Valle | Oct 2006 | A1 |
| 20060251968 | Tsukamoto et al. | Nov 2006 | A1 |
| 20070009801 | Inagaki et al. | Jan 2007 | A1 |
| 20070059587 | Kishi et al. | Mar 2007 | A1 |
| 20070072085 | Chen et al. | Mar 2007 | A1 |
| 20070077496 | Scott et al. | Apr 2007 | A1 |
| 20070111099 | Nanjundaswamy et al. | May 2007 | A1 |
| 20070134556 | Sano et al. | Jun 2007 | A1 |
| 20070162083 | Schmidt et al. | Jul 2007 | A1 |
| 20070233195 | Wahlstrand et al. | Oct 2007 | A1 |
| 20070239221 | Kast et al. | Oct 2007 | A1 |
| 20070248881 | Scott et al. | Oct 2007 | A1 |
| 20070284159 | Takami et al. | Dec 2007 | A1 |
| 20080020278 | Schmidt et al. | Jan 2008 | A1 |
| 20080020279 | Schmidt et al. | Jan 2008 | A1 |
| 20080026297 | Chen et al. | Jan 2008 | A1 |
| 20080044728 | Schmidt et al. | Feb 2008 | A1 |
| 20090035662 | Scott et al. | Feb 2009 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 567 149 | Oct 1993 | EP |
| 0 732 761 | Sep 1996 | EP |
| 0 982 790 | Mar 2000 | EP |
| 1 014 465 | Jun 2000 | EP |
| 1 018 773 | Jul 2000 | EP |
| 1 069 635 | Jan 2001 | EP |
| 1 282 180 | Feb 2003 | EP |
| 1 487 039 | Dec 2004 | EP |
| 1 722 439 | Nov 2006 | EP |
| 56-136462 | Oct 1981 | JP |
| 57-11476 | Jan 1982 | JP |
| 63-1708 | Jan 1982 | JP |
| 57-152669 | Sep 1982 | JP |
| 02-309568 | Dec 1990 | JP |
| 6-275263 | Sep 1994 | JP |
| 10-027626 | Jan 1998 | JP |
| 2000156229 | Jun 2000 | JP |
| 2000-195499 | Jul 2000 | JP |
| 2001-126756 | May 2001 | JP |
| 2001-185141 | Jul 2001 | JP |
| WO 9706569 | Feb 1997 | WO |
| WO 9748141 | Dec 1997 | WO |
| WO 00017950 | Mar 2000 | WO |
| WO 0209215 | Jan 2002 | WO |
| WO 0221628 | Mar 2002 | WO |
| WO 02069414 | Sep 2002 | WO |
| WO 02095845 | Nov 2002 | WO |
| WO 03044880 | May 2003 | WO |
| WO 03075371 | Sep 2003 | WO |
| WO 03090293 | Oct 2003 | WO |
| WO 2006050022 | May 2006 | WO |
| WO 2006050023 | May 2006 | WO |
| WO 2006050098 | May 2006 | WO |
| WO 2006050099 | May 2006 | WO |
| WO 2006050100 | May 2006 | WO |
| WO 2006050117 | May 2006 | WO |
| WO 2006050117 | May 2006 | WO |
| WO 2006064344 | Jun 2006 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20060093894 A1 | May 2006 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60647292 | Jan 2005 | US | |
| 60624075 | Oct 2004 | US |